ENABLE-2 programmes
ENABLE-2 is currently supporting four promising programmes in the pursuit of new antibiotics. These have their scientific basis at: Technische Universität Berlin • Justus Liebig University Giessen • The Ineos Oxford Institute at the University of Oxford • Leiden University & Queen’s University Belfast.
Programme Albisolv
A new type of broad spectrum gyrase inhibitor active against fluoroquinolone-resistant bacteria.
Resident at
Contact
Roderich Süssmuth, Professor, Principal Investigator
Technische Universität Berlin
Roderich.Suessmuth@tu-berlin.de
Programme BamA Inhibitors
Novel antibiotics that hit a new target against Gram-negative bacteria.
Resident at
Contact
Till F. Schäberle, PhD, Principal Investigator
Justus Liebig University Giessen
Till.F.Schaeberle@agrar.uni-giessen.de
Programme Broad-spectrum MBL inhibitors
A new class of broad spectrum metallo-b-lactamase inhibitors that restore activity of carbapenems in MDR Gram-negative Enterobacterales
Resident at
Contact
Alistair Farley, Dr, Scientific Lead
Ineos Oxford Institute at the University of Oxford
Alistair.farley@chem.ox.ac.uk
Christopher Schofield
Professor of Chemistry, University of Oxford
Director of Chemistry, Ineos Oxford Institute at the University of Oxford
Christopher.schofield@chem.ox.ac.uk
Programme Ornicidine
A novel class of anti-bacterial agents active against multi drug-resistant Gram-negative bacteria.
Resident at
Contact
Nathaniel Martin, Professor
Leiden University
n.i.martin@biology.leidenuniv.nl
Stephen Cochrane, Dr.
Queen’s University Belfast
s.cochrane@qub.ac.uk
Learn more
Contact ENABLE-2
Marie Olliver, PhD, Alliance Manager
Uppsala University
Marie.Olliver@ilk.uu.se
ENABLE-2 funders
ENABLE-2 is supported by the Swedish Research Council and the National Research Programme on Antibiotic Resistance.
